Business Context and Reporting Period
Company: Coherus Oncology, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 17, 2026
Event Date: August 12, 2026 (Agreement); August 14, 2026 (Funding)
The Company entered into a new Senior Secured Term Loan facility to refinance existing debt and extend maturity dates beyond anticipated product launch periods.
Key Financial Metrics and Debt Structure
| Metric | Value / Detail |
|---|---|
| New Facility Size (Tranche A) | $55,000,000 |
| Maturity Date | August 2031 |
| Interest Rate | 4.15% + greater of (Prime Rate or 6.75%) |
| Payment Terms | Interest-only for 36 months (extendable to 48 months upon milestones) |
| Facility Fee | 1.50% of funded principal |
| Final Fee | 4.00% of aggregate principal (increases to 10.00% in insolvency scenarios) |
| Collateral | Lien on substantially all assets, including intellectual property |
Material Changes vs. Prior Period
- Debt Refinancing: The Company fully repaid and terminated its Prior Loan Agreement (maturing May 2029) using proceeds from the new facility.
- Interest Rate Reduction: The new interest rate structure is lower than the prior agreement, which accrued interest at 8.0% plus a three-month SOFR rate.
- Maturity Extension: Debt maturity extended from May 2029 to August 2031.
- Incremental Capacity: The principal amount saw a limited incremental increase compared to the prior facility.
Outlook, Management Commentary, and Risks
Management Commentary: The Company states that rolling over senior debt with a limited increase in principal provides financial flexibility for strategic initiatives and aligns debt maturity with pipeline product launch timelines.
Future Funding Options: The Company has the option to draw two additional tranches of $25,000,000 and $20,000,000 under certain conditions.
Prepayment Penalties: Significant prepayment fees apply if the loan is paid off early:
- 5.00% if prepaid within the first anniversary.
- 4.00% if prepaid between the first and second anniversary.
- 3.00% if prepaid between the second and third anniversary.
- 0.00% if prepaid after the third anniversary.
Risks and Covenants: The agreement includes a financial covenant requiring the maintenance of minimum levels of unrestricted cash in collateral accounts. A final fee of 10.00% applies if the Company enters insolvency proceedings and receives debtor-in-possession financing.
Investor Verification Checklist
- Verify the exact interest rate calculation based on current Prime Rate vs. the 6.75% floor.
- Confirm the specific revenue and market capitalization milestones required to extend the interest-only period to 48 months.
- Review the conditions precedent for drawing the optional $25M and $20M tranches.
- Assess the impact of the 1.50% facility fee and 4.00% final fee on total cost of capital.
- Monitor compliance with the minimum unrestricted cash covenant.